BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shargorodsky M, Omelchenko E, Matas Z, Boaz M, Gavish D. Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering? Cardiovasc Diabetol. 2012;11:61. [PMID: 22676459 DOI: 10.1186/1475-2840-11-61] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Ma H, Cui F, Dong JJ, You GP, Yang XJ, Lu HD, Huang YL. Therapeutic effects of globular adiponectin in diabetic rats with nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20:14950-14957. [PMID: 25356056 DOI: 10.3748/wjg.v20.i40.14950] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
2 Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. World J Hepatol. 2015;7:559-565. [PMID: 25848479 DOI: 10.4254/wjh.v7.i3.559] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
3 Fisman EZ, Tenenbaum A. Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease? Cardiovasc Diabetol 2014;13:103. [PMID: 24957699 DOI: 10.1186/1475-2840-13-103] [Cited by in Crossref: 119] [Cited by in F6Publishing: 106] [Article Influence: 17.0] [Reference Citation Analysis]
4 Laugesen E, Høyem P, Christiansen JS, Knudsen ST, Hansen KW, Argraves WS, Hansen TK, Poulsen PL, Rasmussen LM. Plasma levels of the arterial wall protein fibulin-1 are associated with carotid-femoral pulse wave velocity: a cross-sectional study. Cardiovasc Diabetol 2013;12:107. [PMID: 23866070 DOI: 10.1186/1475-2840-12-107] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
5 Zarzour RHA, Alshawsh MA, Asif M, Al-Mansoub MA, Mohamed Z, Ahmad M, Majid AMSA, Asmawi MZ, Kaur G, Al-Dualimi DW, Yam MF. Adipocytokine Regulation and Antiangiogenic Activity Underlie the Molecular Mechanisms of Therapeutic Effects of Phyllanthus niruri against Non-Alcoholic Fatty Liver Disease. Nutrients 2018;10:E1057. [PMID: 30096951 DOI: 10.3390/nu10081057] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
6 Ozturk ZA, Kadayifci A. Insulin sensitizers for the treatment of non-alcoholic fatty liver disease. World J Hepatol. 2014;6:199-206. [PMID: 24799988 DOI: 10.4254/wjh.v6.i4.199] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 5.9] [Reference Citation Analysis]
7 Mirrakhimov AE. Nonalcoholic fatty pancreatic disease and cardio-metabolic risk: is there is a place for obstructive sleep apnea? Cardiovasc Diabetol 2014;13:29. [PMID: 24475948 DOI: 10.1186/1475-2840-13-29] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
8 Shen Y, Ma X, Zhou J, Pan X, Hao Y, Zhou M, Lu Z, Gao M, Bao Y, Jia W. Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. Cardiovasc Diabetol 2013;12:124. [PMID: 23981342 DOI: 10.1186/1475-2840-12-124] [Cited by in Crossref: 81] [Cited by in F6Publishing: 73] [Article Influence: 10.1] [Reference Citation Analysis]
9 Di Paola R, Marucci A, Fontana A, Menzaghi C, Salvemini L, Copetti M, Pellegrini F, De Cosmo S, Trischitta V. Role of obesity on all-cause mortality in whites with type 2 diabetes from Italy. Acta Diabetol 2013;50:971-6. [DOI: 10.1007/s00592-013-0509-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
10 Takayama H, Misu H, Iwama H, Chikamoto K, Saito Y, Murao K, Teraguchi A, Lan F, Kikuchi A, Saito R, Tajima N, Shirasaki T, Matsugo S, Miyamoto K, Kaneko S, Takamura T. Metformin suppresses expression of the selenoprotein P gene via an AMP-activated kinase (AMPK)/FoxO3a pathway in H4IIEC3 hepatocytes. J Biol Chem 2014;289:335-45. [PMID: 24257750 DOI: 10.1074/jbc.M113.479386] [Cited by in Crossref: 46] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
11 Gajdova J, Karasek D, Goldmannova D, Krystynik O, Schovanek J, Vaverkova H, Zadrazil J. Pulse wave analysis and diabetes mellitus. A systematic review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2017;161:223-33. [DOI: 10.5507/bp.2017.028] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
12 Rouabhia S, Milic N, Abenavoli L. Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism. Expert Review of Gastroenterology & Hepatology 2014;8:343-9. [DOI: 10.1586/17474124.2014.894880] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
13 Anil TM, Harish C, Lakshmi MN, Harsha K, Onkaramurthy M, Sathish Kumar V, Shree N, Geetha V, Balamurali GV, Gopala AS, Madhusudhan Reddy B, Govind MK, Anup MO, Moolemath Y, Venkataranganna MV, Jagannath MR, Somesh BP. CNX-012-570, a direct AMPK activator provides strong glycemic and lipid control along with significant reduction in body weight; studies from both diet-induced obese mice and db/db mice models. Cardiovasc Diabetol 2014;13:27. [PMID: 24460834 DOI: 10.1186/1475-2840-13-27] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
14 Eskens BJ, Zuurbier CJ, van Haare J, Vink H, van Teeffelen JW. Effects of two weeks of metformin treatment on whole-body glycocalyx barrier properties in db/db mice. Cardiovasc Diabetol 2013;12:175. [PMID: 24308370 DOI: 10.1186/1475-2840-12-175] [Cited by in Crossref: 49] [Cited by in F6Publishing: 38] [Article Influence: 6.1] [Reference Citation Analysis]
15 Zhang L, She ZG, Li H, Zhang XJ. Non-alcoholic fatty liver disease: a metabolic burden promoting atherosclerosis. Clin Sci (Lond) 2020;134:1775-99. [PMID: 32677680 DOI: 10.1042/CS20200446] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
16 Lunder M, Janić M, Šabovič M. Treating Arterial Ageing in Patients with Diabetes: From Mechanisms to Effective Drugs. Int J Mol Sci 2021;22:2796. [PMID: 33801956 DOI: 10.3390/ijms22062796] [Reference Citation Analysis]
17 Dludla PV, Nkambule BB, Mazibuko-Mbeje SE, Nyambuya TM, Mxinwa V, Mokgalaboni K, Ziqubu K, Cirilli I, Marcheggiani F, Louw J, Tiano L. Adipokines as a therapeutic target by metformin to improve metabolic function: A systematic review of randomized controlled trials. Pharmacol Res 2021;163:105219. [PMID: 33017649 DOI: 10.1016/j.phrs.2020.105219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Zheng J, Woo SL, Hu X, Botchlett R, Chen L, Huo Y, Wu C. Metformin and metabolic diseases: a focus on hepatic aspects. Front Med 2015;9:173-86. [PMID: 25676019 DOI: 10.1007/s11684-015-0384-0] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 8.2] [Reference Citation Analysis]
19 Boutari C, Perakakis N, Mantzoros CS. Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease. Endocrinol Metab (Seoul). 2018;33:33-43. [PMID: 29589386 DOI: 10.3803/enm.2018.33.1.33] [Cited by in Crossref: 61] [Cited by in F6Publishing: 35] [Article Influence: 20.3] [Reference Citation Analysis]
20 Ferolla SM, Couto CA, Costa-Silva L, Armiliato GN, Pereira CA, Martins FS, Ferrari Mde L, Vilela EG, Torres HO, Cunha AS, Ferrari TC. Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis. Nutrients 2016;8:E397. [PMID: 27367724 DOI: 10.3390/nu8070397] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 9.8] [Reference Citation Analysis]
21 Huang Y, Yang G, Wang C, Chen X, Zhang L. Effectiveness of drug interventions in nonalcoholic fatty liver disease: A network meta-analysis. WJD 2021;12:1576-86. [DOI: 10.4239/wjd.v12.i9.1576] [Reference Citation Analysis]
22 Mosińska P, Jacenik D, Sałaga M, Wasilewski A, Cygankiewicz A, Sibaev A, Mokrowiecka A, Małecka-panas E, Pintelon I, Storr M, Timmermans JP, Krajewska WM, Fichna J. FABP4 blocker attenuates colonic hypomotility and modulates white adipose tissue-derived hormone levels in mouse models mimicking constipation-predominant IBS. Neurogastroenterol Motil 2018;30:e13272. [DOI: 10.1111/nmo.13272] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
23 Ahadi S, Gharekhani A, Shiva A. Treatments of nonalcoholic fatty liver disease in adults who have no other illness: A Review article. Arab Journal of Gastroenterology 2019;20:189-97. [DOI: 10.1016/j.ajg.2019.11.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]